In PNH the market is not sized by prevalence. It is sized by how many patients have had the flow-cytometry test that confirms the diagnosis, and most have not.
PNH is an acquired clonal disorder whose presenting features - fatigue, haemoglobinuria and thrombosis - mimic far more common conditions. Confirmation requires high-sensitivity flow cytometry for GPI-anchor-deficient cells, a test that sits outside the standard anaemia and thrombosis work-up. Most patients are therefore diagnosed only after an unexplained haemolytic or thrombotic event routes them to haematology, often years after symptom onset. The referral-and-testing pathway, not efficacy or price, is the rate-limiting step in this market.
Treatment has divided into two mechanisms. Intravenous anti-C5 antibodies have held the majority of diagnosed patients since the class was established, and an oral Factor B inhibitor has since opened a switch that the class cannot answer on convenience alone. The live commercial opportunity is not the market at large but a specific cohort: patients with extravascular haemolysis who remain anaemic on intravenous anti-C5 therapy. Modelled as a subpopulation conversion, that cohort behaves nothing like a share-of-market contest, and an analogue curve borrowed from a larger indication will overstate uptake substantially.
The payer case does not transfer between markets. In the United States it turns on whether an agent routes through the medical or the pharmacy benefit, on prior-authorisation criteria that are still forming, and on the orphan-drug exclusion that shields the class from Medicare negotiation. In the United Kingdom it runs through the ultra-rare appraisal route with its own threshold. In the Gulf the gate is registration and payer infrastructure, which lag both.
AXLRx PNH reports build that funnel end to end, size the switch cohort with testing rate as an explicit sensitivity, and construct the value case market by market.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
PNH diagnosis pathway, FLAER flow-cytometry bottleneck and the treated-prevalent pool across US centres.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
Anti-C5 IV therapy holds the GCC PNH market under NPHC and MOH specialist-centre gating. Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary.
NPHC's KSA-first coverage model sets the de facto GCC access bar for anti-C5 agents. Iptacopan faces a 12-24 month SFDA registration queue before NPHC even evaluates it.
Iptacopan reached French PNH patients through early access, before EU marketing authorisation took effect. HAS granted accès précoce two weeks ahead of it. Any new PNH entrant must be dossier-ready for this track before, not after, EU approval.
Leeds National Registry data, FLAER access without referral, and the 30% PNH-aplasia overlap defining the NHS commercial picture.
Iptacopan's substantial-benefit finding gave Germany real negotiating leverage over Novartis. Six months on, no negotiated net price has surfaced in the Lauer-Taxe — the pricing signal this model is built to catch before a launch-sequencing decision locks in the wrong assumption.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000). The real payer question is how fast the NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal at the ordinary £20,000–£30,000/QALY bar.
Binding constraint: beat iptacopan's oral bar in the EVH-anaemia cohort anti-C5 can't resolve — inside a pricing ceiling iptacopan already set.
15,000-20,000 Americans carry a PNH clone, but only about 3,500 reach complement-inhibitor therapy. Up to 1,200 of them stay anaemic on it. This model sizes every gap in between.
~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500. The other 750-900 are monitored-only or undiagnosed, and this model sizes the gap.
France's PMSI hospital database counts 897 PNH patients over five years; Orphanet's older estimate puts national prevalence at 850-1,000. Only 270 of them, per the manufacturer's own estimate, are eligible for a second-line oral agent.
NICE has cleared every modern PNH anti-complement therapy through the standard £20,000-30,000 Technology Appraisal route. From ravulizumab to crovalimab, none used the more generous Highly Specialised Technologies threshold, and each went via a confidential patient access scheme.
GCC anti-C5 tender pricing already runs 40-60% of US WAC, anchored to whichever EU comparator prices lowest. A further 10-20% negotiation discount compounds it. Iptacopan has to clear the same cascade, still 12-24 months from SFDA registration.
HAS reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds first-line. France split the anti-complement class by line of therapy, not by price.
France's PMSI hospitalisation database identified 897 PNH patients between 2018 and 2022, putting prevalence near 1 in 94,000. That is below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan have long cited.
First-mover oral complement inhibition in GCC PNH is a closing window. SFDA registration ahead of iptacopan, not competitive differentiation from entrenched anti-C5, decides commercial success.
All three UK PNH agents cleared NICE via the standard Technology Appraisal route, not the ultra-rare one. Ravulizumab (TA698), iptacopan (TA1000) and crovalimab all took it. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share.
Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.
Germany's DGHO Onkopedia guideline states plainly that Germany-specific PNH prevalence and incidence figures do not exist. It borrows 16 cases and 1.3 new diagnoses per million annually from British and French registries, and routes all case-finding through just two national centres, Ulm and Essen.
An estimated 2,000-3,000 Gulf patients carry a clinically significant PNH clone. Only about 400 are confirmed in national registries, and just 150-250 reach complement-inhibitor therapy. Diagnostic capacity, not drug access, is the constraint this model sizes.
Ultomiris cannot resolve the EVH-dominant PNH population, and that gap defines the UK opportunity. Every PNH agent has now cleared the standard NICE Technology Appraisal bar; this sizes the PAS discount required to hit it before MHRA approval.
Iptacopan's ~$550,000 annual WAC sits roughly 71% above ICER's $156,000-157,000 value-based benchmark. The orphan-drug exclusion keeps anti-C5 incumbents outside IRA's reach entirely. Those are the two forces any new US PNH entrant must price against.
The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy. A broader estimate cited in AXLRx's own Launch Readiness research puts it near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question.
PNH diagnostic pathway, FLAER flow-cytometry bottleneck and the undiagnosed clonal pool across GCC specialist centres.
Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres.
Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit.
US PNH prevalence spans 15,000 to 20,000 patients across three phenotypes, but only about 3,500 are on complement-inhibitor therapy. A 2.4-year average diagnostic delay, plus 200 to 400 patients a year undertreated at non-PNH centres, accounts for most of that gap.
France's national hospitalisation database puts PNH prevalence near 1 in 94,000, or 897 patients from 2018 to 2022. That is lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
Iptacopan already cleared Germany's AMNOG process with a substantial benefit finding and no comparator dossier. A new entrant without orphan-pathway standing has to win that same finding the hard way, through IQWiG.
France prices PNH on two tracks. Ravulizumab holds first-line; iptacopan is reimbursed second-line only, and reached patients through early access two weeks before its EU marketing authorisation took effect.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
Saudi Arabia's rare disease registry counts about 400 confirmed PNH cases. Global prevalence rates, adjusted for the region's 25-50% consanguinity rate, imply a true GCC PNH population 20-30% higher, and fewer than 15 labs across six countries can even run the diagnostic test.
Germany has no domestic PNH prevalence count of its own. DGHO's Onkopedia guideline borrows a 16-per-million estimate from British and French registries, and only two national centres, Ulm and Essen, anchor referral.
NICE has cleared all four modern PNH anti-complement therapies through its standard £20,000-30,000 Technology Appraisal route. Ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision.
France reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds the first-line position. The restriction, not the price, is what defines the addressable population.
Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare acquired clonal hematopoietic stem-cell disorder, with an estimated ~18,000 diagnosed patients in the US. The true number is uncertain: PNH is frequently missed because its hallmark features (fatigue, hemoglobinuria, and thrombosis) mimic far more common conditions, and confirmation requires a flow-cytometry test that is not routinely ordered. The gap between the epidemiological and the diagnosed population is the single most important number to get right in PNH commercial work.
PNH is confirmed by high-sensitivity flow cytometry detecting GPI-anchor-deficient blood cells. Because the presenting symptoms are non-specific and the test is not part of a standard anemia or thrombosis work-up, most patients are diagnosed only after an unexplained hemolytic or thrombotic event routes them to hematology, often years after symptom onset. For a commercial team, the referral-and-testing pathway (who orders flow cytometry, and when) is the true rate-limiting step, upstream of any question about efficacy or price.
Four agents are approved: eculizumab (Soliris, AstraZeneca) and ravulizumab (Ultomiris, AstraZeneca), both intravenous anti-C5 monoclonal antibodies; iptacopan (Fabhalta, Novartis), the first oral Factor B inhibitor, approved in 2023; and crovalimab (Piasky, Roche/Chugai), a subcutaneous anti-C5 antibody approved in 2024. The anti-C5 class has historically covered roughly 60-70% of diagnosed patients, and the commercial contest now centres on the oral switch dynamic that iptacopan introduced.
Not from prevalence. In an ultra-rare, diagnosis-limited disease the defensible number is built bottom-up as a funnel: diagnosed prevalence, then the treated pool, then the specific subpopulation your asset targets, in PNH the ~1,000 patients with extravascular hemolysis (EVH) who remain anemic on IV anti-C5 and are the oral switch candidates. The variable that moves this number most is not efficacy but flow-cytometry testing penetration and referral rate. Any PNH forecast that assumes full diagnosis overstates the near-term addressable pool, and the sizing has to be shown as a sensitivity on the testing rate, not a single point estimate.
Model it as a subpopulation conversion, not a share grab. The realistic near-term opportunity is the EVH-dominant cohort transfusing despite IV C5 therapy, so the forecast is built patient-by-patient off that funnel and off the timing of payer step-edit and prior-authorization criteria, which form gradually and gate the switch. Because the anti-C5 price anchor is shielded from IRA Medicare negotiation by the orphan-drug exclusion, oral entry is additive to a stable-priced class rather than a price war. Anchoring an oral-switch forecast on a large-indication analog curve consistently overstates uptake in PNH.
Geo by geo, because the frameworks do not transfer. In the US, the case is built around Part B (IV buy-and-bill) versus Part D (oral) routing, the forming PA and step-edit criteria, and the orphan-drug IRA exclusion that keeps the class anchor intact; ICER's value benchmark (~$156K-157K) is the reference point to argue against. In the UK, PNH agents run through NICE's Highly Specialised Technologies route with its distinct cost thresholds. In the GCC, the gate is SFDA registration and payer infrastructure, which typically lag US and EU access. The value story rests on the transfusion-burden offset in a defined subpopulation, not a whole-population claim.
Because in PNH the addressable market is defined by the patient-identification funnel, not by prevalence, and the live opportunity is a specific subpopulation rather than the market at large. Analog curves borrowed from larger indications assume a findable, fully-diagnosed population and a broad treated pool, both false here. The disciplined approach is a bottom-up model where diagnosis rate, testing penetration, and subpopulation size are the explicit levers, each defensible in a forecast review. In rare disease the funnel is the strategy; the label is not.
The analysis behind the questions above: a bottom-up patient-flow model from diagnosed prevalence to the EVH switch cohort with testing-rate sensitivities; competitive intelligence on the forming PA and step-edit dynamics; a payer and HTA value case built market by market for the US, UK, and GCC; KOL and treatment-centre mapping; and pricing analysis against the ICER benchmark. Each is scoped to your asset and its target subpopulation, delivered as a sourced brief, an editable model, or an executive readout.